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Abstract 
Introduction: Subclinical hyperthyroidism (SCH), also known as mildly symptomatic hyperthyroidism, has recently been diagnosed 
more frequently. One of the main endogenous causes of this disorder is autonomously functioning thyroid nodule (AFTN). Despite the 
fact that it is usually asymptomatic, SCH entails repercussions on the cardiovascular system and bone, and it carries a risk of progression 
to overt hyperthyroidism with a typical clinical picture. Treatment is still controversial, and its benefits are widely debated in literature. 
Material and methods: From 459 patients authors selected a group of 49 patients (10.6% of all subjects with hyperthyroidism), 41 women 
(83.7%) with AFTN at the stage SCH treated in the Outpatient Endocrinological Clinic and the Department of Endocrinology of the 
Medical University of Lublin over a three-year period. The method applied in the study was a retrospective analysis of medical records 
with a particular account of medical history, physical examination, and additional tests obtained during the process of diagnostic and 
therapeutic procedures.
Results: Forty-one patients (83.7%) suffered from typical symptoms of hyperthyroidism; only eight patients (16.3%) were asymptomatic. 
The most frequently reported symptoms were tachycardia in women (51.2%) and anxiety in men (50%). The type of thyrostatic drugs and 
the length of therapy did not affect the outcome of iodine-131 therapy. In the vast majority of the patients (87.8%) radioidodine therapy 
was effective; 30 patients (61.2%) reached euthyreosis and 13 patients (22.5%) developed hypothyroidism.
Conclusions: Most patients with SCH in the course of AFTN suffered from typical symptoms of overt hyperthyroidism; only every sixth 
patient was asymptomatic. The volume of autonomous adenomas did not affect the result of 131I therapy; however, the impact of AFTN 
volume as well as the thyroid volume on RIT efficacy requires futher investigation. In the vast majority of patients 131I therapy was an ef-
fective method of treatment, and an earlier therapeutic effect was observed more often in the patients with focal lesions located in the 
right lobe. (Endokrynol Pol 2019; 70 (2): 157–164)
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Introduction 
Subclinical hyperthyroidism (SCH), also called mildly 
symptomatic hyperthyroidism, in the past years has 
been diagnosed more frequently. One of the main 
endogenous causes of this disorder is autonomously 
functioning thyroid nodule (AFTN) [1, 2]. Diagnosis 
is established only under certain laboratory crite-
ria, i.e. persistently low TSH level confirmed with 
third-generation tests and normal level of free thyroid 
hormones [3]. AFTN, defined as a hot nodule in thyroid 
scintigraphy, is characterised by excessive production of 
hormones, which suppresses TSH secretion and leads 
to inhibition of hormone synthesis by the remainder 
of the gland and results in either overt or subclinical 
hyperthyroidism. It is usually a benign follicular lesion 
(90–95%) or a hyperplastic nodule (5–10%), less often 
autonomous carcinoma, irrespective of the activity of 
the hypothalamic–pituitary–adrenal axis [4, 5]. SCH has 
gained more attention after publication of the results of 
a systematic review with a meta-analysis of 10 prospec-
tive cohort studies from 2012, pointing to its association 
with higher total and cardiovascular mortality as well 
as atrial fibrillation as compared to healthy controls 
[6, 7]. However, it is emphasised that over 25% of such 
nodules do not produce symptoms of general thyro-
toxicosis. SCH may take the form of a primary onset 
of the disorder leading to overt hyperthyroidism ac-
companied by few or even no clinical symptoms. They 
are mainly associated with cardiovascular diseases like 
tachycardia or supraventricular arrhythmia, detected 
in electrocardiographic investigation [8]. An analysis 
of the clinical symptoms reported by the patients may 
give valuable information about the expected clinical 
course of AFTNs. Despite potential cardiovascular and 
bone complications or even progression to overt hy-
perthyroidism, the need to treat SCH is still debatable. 
Treating this form of disease is currently perceived as 
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were determined by radioimmunoassay (RIA) with solid phase 
antigen radioimmunometric technique (SPART) (B.R.A.H.M.S FT3 
SPART RIA, B.R.A.H.M.S FT4 RIA) with the use of a coated-tube 
system. The level of TRAb/TSI was measured by radioreceptor assay 
(RRA) used for the quantitative method of measurement of TRAb 
(B.R.A.H.M.S) using a human TSH receptor (B.R.A.H.M.S Track 
human RIA). The levels of antibodies against thyroid peroxidase 
were determined by RIA with the B.R.A.H.M.S anti-TPO RIA kit.
Methods of imaging
Thyroid ultrasound was performed using a 7.5-MHz linear probe 
for the LOGIQ P5 machine. A solution of 74 MBq of 99mTcO4 was 
injected intravenously. Scintigraphy was performed using a gamma 
camera with a small field of view. For 131I uptake test, capsules of 4 
MBq of sodium iodide Na131I were administered orally, and iodine 
uptake was measured after 24, 48, and 72 hours. 
Ultrasound-guided fine-needle aspiration biopsy
In accordance with the recommendations of the Scientific Com-
mittee of the Scientific Conference “Thyroid Cancer”, 32 patients 
(65%) with suspected focal lesions diagnosed by palpation and/or 
with thyroid ultrasound underwent ultrasound-guided FNAB [10]. 
Radioiodine therapy
The therapeutic activity of 131I was calculated on the basis of 
Marinelli’s formula, in which a dose 300 Gy was for each gram of 
hyperactive thyroid tissue. The subjects with AFTNs were qualified 
to RIT in accordance with the official recommendations.
Criteria for recovery and rules for monitoring patients after  
administrating 131I
Criteria of recovery included normal thyroid function (TSH, FT4, 
and FT3 levels within range) as well as a less expected effect of 
treatment i.e. hypothyroidism. All patients were evaluated for 
possible complications, in particular: aggravation of hyperthyroid 
symptoms including atrial fibrillation, circulatory failure, thyroid 
crisis, radiation-induced thyroiditis, and symptoms of sialadenitis.
In accordance with the procedure of 131I therapy, each patient was 
monitored in an outpatient clinic at certain intervals i.e. after one, 
three, six, and 12 months.  
Statistical analysis
The values of non-measurable parameters were presented by means 
of numbers and percentages, whereas the measurable ones used 
the arithmetic mean, standard deviation, median, as well as the 25th 
and 75th percentile along with the range of variability. To evaluate 
controversial, and arbitrary recommendations of inter-
national endocrine associations are questioned by many 
experts in the field. At the same time the evaluation of 
the benefits from SCH treatment is often ambiguously 
presented in literature [9].
The main objective of the study was to evaluate 
the clinical picture of AFTNs in SCH and its optimal 
treatment. 
Material and methods 
Study protocol
The method applied in the study was a retrospective analysis of 
medical records with a particular account of medical history, physi-
cal examination, and additional tests obtained during the process 
of diagnostic and therapeutic procedures.
Medical records of the patients were evaluated for:
 — age at diagnosis (patient’s age) and duration of the disease;
 — family history of thyroid disease;
 — subjective clinical signs and co-morbidities;
 — TSH, FT4, and FT3 levels at diagnosis and during treatment;
 — presence of antithyroid antibodies: anti-thyroid peroxidase 
antibodies, (anti-TPO antibodies), and TSH-receptor autoan-
tibodies (TRAb);
 — thyroid ultrasound and scintiscans;
 — ultrasound-guided fine-needle aspiration biopsy (FNAB);
 — method of treatment before radioiodine therapy (RIT, 131I );
 — qualification for treatment with RIT;
 — evaluation of patient’s prognosis after RIT.
The patients underwent physical examination for typical clinical 
signs of hyperthyroidism. 
Diagnosis of SCH was confirmed with the levels of TSH, FT4, and 
FT3 in accordance with the endocrinological standards. Other causes 
of low TSH were excluded. They were: overt hyperthyroidism, 
gestation, thyroiditis, mental illness, central hypothyroidism, and 
secondary thyroid syndromes in the course of neoplasms, fever, 
liver disease, and starvation. 
The results of biochemical tests and diagnostic imaging (thyroid 
ultrasound and scintigraphy) performed at the Radiology and 
Nuclear Medicine Centre of the Medical University of Lublin were 
used in the study.
In accordance with the recommendations of the Scientific Commit-
tee of the Scientific Conference “Thyroid Cancer”, 32 patients (65%) 
with suspected focal lesions diagnosed by palpation and/or with 
thyroid ultrasound underwent FNAB. Family history included the 
prevalence of thyroid disease in first-degree relatives.
Study population
Initially, we reviewed a group of 459 patients with diagnosed 
hyperthyroidism (ICD E.05) treated in the Outpatient Endocrino-
logical Clinic and the Department of Endocrinology of the Medical 
University of Lublin during a three-year-long period, i.e. from 
October 2010 to June 2013. Next, a group of 291 (63.4%) patients 
with a toxic goitre was pooled. From this group we singled out 49 
patients (10.6% of all subjects with hyperthyroidism), 41 women 
(83.7%) and 8 men (16.3%), who suffered from AFTN and were 
qualified for 131I treatment, as shown in Figure 1. We excluded 
patients with contraindications to 131I therapy, with either rela-
tive ones (uncontrolled hyperthyroidism, excessive iodine intake 
induced hyperthyroidism, patients younger than 16 years of age) 
or with absolute ones (gestation, breastfeeding). 
Methods of laboratory test measurements 
Blood serum level of TSH was measured by immunoradiometric 
assay (B.R.A.H.M.S TSH 1 RIA). The levels of FT3 and FT4 in serum 
Figure 1. Phenotype analysis of the study group
Excluded patients Women Men
16.3%
83.7%
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statistical differences and correlations between the non-measurable 
parameters, cross tabulation and a chi-squared test were applied. 
While, to compare the measurable variables, we performed the 
Mann-Whitney U test for two independent groups, whereas the 
Kruskal-Wallis test and a post-hoc analysis were used for multiple 
comparisons. The adopted significance level was 5%. The statisti-
cal analysis was performed with the StatSoft, Poland Statistica v. 
10.0 software. 
Results 
Clinical characteristics of the study group
The median age in women was insignificantly lower 
than in men, whereas the median of the time of obser-
vation between qualification procedures and RIT in 
the whole group was 37 days, which was insignificant 
in terms of gender (Tab. I). Only nine patients (18.4%) 
reported family history of thyroid disease. Further 
evaluation showed that the time median was three 
months and the duration of treatment in women was 
insignificantly longer than in men, as shown in Table 
I. In the study group 30 patients (61.2%) were treated 
with thyrostatics, as shown in Table I. 
Thyroid characteristics of the study group 
Thyroid evaluation of the study group included both 
the results of imaging and biochemical tests, as shown 
in Table I. TSH level before the treatment in the whole 
study group was suppressed, while FT4 and FT3 levels 
were normal. Both in women and in men the right 
lobe was larger. However, the volume of the left lobe 
in women was insignificantly greater than in men. The 
mean volume of the autonomous adenoma was 4.24 ml 
(1.27–9.25 ml) with no significant difference in terms 
of gender, which constituted 16.9% and 23.3% of the 
whole thyroid tissue in women and men, respectively. 
In most of the patients (29 subjects, 59.2%) adenoma 
was located in the right lobe, whereas in 20 subjects 
(40.8%) it was in the left lobe. In all men the nodule was 
found in the right lobe, and in women it was distributed 
equally. Thyroid FNAB was performed in 32 patients, 
which constituted 65% of the whole group, i.e. in 75% 
of men and 63.4% of women.  All biopsy specimens 
were found benign.
Clinical symptoms in the course of SCH
Forty-one patients (83.7%) suffered from typical symp-
toms of hyperthyroidism, and only eight patients 
(16.3%) were asymptomatic. The most frequently 
reported symptom in women was tachycardia (51.2%) 
while in men (50%) it was anxiety — as shown in 
Table II.
Table I. Characteristics of the study group
Parameter Women median (range) Men median (range) Total median (range) p
Age [years] 59.0 (52.00–67.00) 63.5 (56.00–75.00) 59.0 (52.00–68.00) 0.28
Treatment length [months] 3.00 (0.00–6.00) 2.5 (0.00–7.50) 3.00 (0.00–7.00) 1.0
Period of time from 
scintigraphy to iodine 
administration [days]
37.0 (15.00–113.00) 36.00 (28.00–66.00) 37.0 (17.00–93.00) 0.78
Patients treated 
with thyrostatics
25 (60.9%)  
(51.0% of all patients)
5 (62.5%)  
(10.2% of all patients)
30  
(61.2% of all patients) 0.75
TSH before treatment [mlU/L] < 0.04 (0.04–0.25) < 0.04 (0.04–0.04) < 0.04 (0.04–0.18) 0.37
FT4 before treatment [pmol/L] 18.00 (15.70–19.40) 16.65 (15.60–21.00) 17.60 (15.70–19.40) 0.60
FT3 before treatment [pmol/L] 6.30 (5.80–6.70) 6.50 (6.00–8.70) 6.30 (5.80–6.80) 0.27
aTPO [U/mL] 30.9 (21.45–75.7) 53.00 (26.00–67.5) 33.25 (22.1–75.2) 0.73
TSI [U/mL] 0.30 (0.30–0.60) 0.35 (0.3–0.65) 0.3 (0.3–0.6) 0.57
Volume of the whole thyroid 
[mL] 29.22 (15.19–42.23) 46.75 (23.81–68.91) 32.23 (16.09–47.82) 0.09
Size of the right lobe [mL] 13.01 (7.22–24.58) 23.92 (11.59–46.68) 13.1 (8.87–29.49) 0.13
Size of the left lobe [mL] 9.22 (5.48–19.59) 7.51 (3.46–49.36) 9.22 (5.38–19.59) 0.81
Volume of adenoma [mL] 4.24 (0.96–8.88) 4.97 (3.08–36.90) 4.24 (1.27–9.25) 0.39
Size of adenoma  
in the thyroid (%) (16.92%) (4.74–2.65) (23.32%) (12.02–44.74) (17.1%) (6.72–34.51) 0.42
Location of adenoma Left lobe  20 (48.8%)
Right lobe  
21 (51.2%)
Left lobe  
0 (0%)
Right lobe  
8 (100%)
Left lobe  
20 (40.8%)
Right lobe  
29 (59.2%) 0.03
Ultrasound-guided FNAB 26 (63.4%) 6 (75.0%) 32 (65.3%) 0.82
TSH — thyroid stimulating hormone; FT3 — free triiodothyronine; FT4 —  free thyroxine; aTPO — anti-thyroid peroxidase antibodies; TSI — thyroid stimulating 
immunoglobulin; FNAB — ultrasound-guided fine-needle aspiration biopsy; Data are presented as median (interquartile range) and N (%)
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The occurrence of coexistent symptoms in one pa-
tient was analysed as shown in Table III.
Eight patients (16.3%) were completely asymptom-
atic. Three patients (6.1%) suffered from one symptom, 
and only one patient (2.0%) suffered from the maximum 
number of symptoms – nine. Prevalence of four symp-
toms in one patient was observed in 17 subjects (34.7%). 
Effects of 131I treatment 
One month after 131I therapy 19 patients (38.8%) re-
verted to euthyroidism, two patients (4.1%) developed 
hypothyroidism, and 28 patients (57.1%) still suffered 
from SCH (Tab. IV). 
After three months 32 patients (65.3%) reverted to 
euthyroidism, seven patients (14.3%) developed hypo-
thyroidism, and only 10 patients (20.4%) still suffered 
from SCH.
After six months as many as 33 patients (67.4%) re-
verted to euthyroidism, 10 patients (20.4%) developed 
hypothyroidism, and only six patients (12.2%) still suf-
fered from SCH.
After 12 months 30 patients (61.2%) reverted to 
euthyroidism, 13 patients (26.5%) developed hypothy-
roidism, and six patients (12.2%) still suffered from SCH.
In majority of patients (87.8%) RIT was effective.
To sum up, after the complete follow-up, targeted 
therapeutic results were observed in 43 patients (87.8%); 
30 patients (61.2%) reverted to euthyreosis and 13 pa-
tients (22.5%) became hypothyroid, as shown in Table V 
and Figure 2.
Relationship between 131I therapy efficacy, gen-
der, positive thyroid history, and location of the 
nodule
In the analysis of the efficacy of 131I therapy after one, 
three, six, and 12 months with regard to patient’s gen-
der, positive thyroid history, and location of the nodule 
as well as whether the subjects reverted to euthyroidism 
or developed hypothyroidism with regard to patient’s 
gender, positive thyroid history and location of the 
nodule, the treatment was found effective only one 
or three months after the therapy in the patients with 
focal lesions in the right lobe.
Discussion 
The results of our study point to the symptomatic course 
of AFTNs in SCH despite persistent normal thyroid 
hormones. In the study group most patients (83.7%) 
suffered from typical symptoms of hyperthyroidism, 
and only every sixth patient was asymptomatic. Stott 
et al. presented similar results for patients aged 61–90 
years with SCH as compared to healthy controls [11]. 
In the study by Biondi et al. the scores of the Symptoms 
Rating Scale and the Short Form 36 Health Survey 
Table III. Prevalence of coexistent symptoms in one patient
Number of symptoms Number of patients Percentage (%)
0 8 16.3%
1 3 6.1%
2 2 4.1%
3 8 16.3%
4 17 34.7%
5 6 12.2%
6 3 6.1%
7 1 2.0%
8 1 2.0%
Total 49 100%
Table II. Clinical symptoms in the study group
Symptoms
Women Men Total
N (%) N (%) N (%)
Periodical heart palpitation 21 (51.2%) 3 (37.5%) 24 (49%)
Weakness 20 (48.9%) 3 (37.5%) 23 (47%)
Unintentional weight loss 14 (34.1%) 3 (37.5%) 17 (34.7%)
Excessive sweating 14 (34.1%) 3 (37.5%) 17 (34.7%)
Emotional lability 13 (31.7%) 4 (50%) 17 (34.7%)
Reduced exercise tolerance 13 (31.7%) 3 (37.5%) 16 (32.7%)
Shortness of breath 11 (26.8%) 0 (0%) 11 (22.4%)
Chest pain 10 (24.4%) 0 (0%) 10 (20.4%)
Insomnia 9 (22%) 0 (0%) 9 (18.4%)
Heat intolerance 7 (17.1%) 2 (25%) 9 (18.4%)
Difficulty swallowing 8 (19.5%) 1 (12.5%) 9 (18.3%)
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questionnaires showed increasing prevalence of typi-
cal symptoms of hyperthyroidism that worsened the 
quality of life of the patients, which correlated with TSH 
levels [12, 13]. Gulseren et al. presented worse results 
of both mental and physical tests performed by SCH 
patients as compared to the control group [14]. In the 
clinical picture of hyperthyroidism literature stresses 
greater frequency of symptoms related to the adrenergic 
overactivity expressed most often by heart palpitation 
present particularly in young and middle-aged pa-
tients. In the study group the feeling of tachycardia was 
the most frequently reported sign in women (52.2%) 
and one of the most common in men (37.5%). In their 
study, Sgarbi et al. found a significant increase in atrial 
and ventricular premature beats in SCH patients and 
observed that TSH and FT4 significantly correlated with 
such premature beats [15]. The meta-analysis conducted 
by Collet et al. showed higher total and cardiovascular 
mortality and prevalence of atrial fibrillation in SCH 
patients as compared to healthy controls [6]. Such 
documented effect of SCH on the cardiovascular system 
suggests considering treatment also in young patients 
Table IV. Effects of 131I treatment after 1, 3, 6, and 12 months
Parameter Women N (%) Men N (%) Total N (%) p
1 month after treatment
Euthyreosis 17 (41.5%) (34.7% of all patients)
2 (25.0%) 
(4.1% of all patients)
19  
(38.8% of all patients)
0.34Hypothyroidism 1 (2.4%) (2.0% of all patients)
1 (12.5%) 
(2.0% of all patients)
2  
(4.1% of all patients)
Hyperthyroidism 23 (56.1%) (46.9% of all patients)
5 (62.5%) 
(10.2% of all patients)
28 
(57.1% of all patients)
3 months after treatment
Euthyreosis 26 (63.4%) (53.1% of all patients)
6 (75.0%) 
(12.2% of all patients)
32 
(65.3% of all patients)
0.80Hypothyroidism 6 (14.6%) (12.2% of all patients)
1 (12.5%) 
(2.0% of all patients)
7 
(14.3% of all patients)
Hyperthyroidism 9 (21.9%) (18.4% of all patients)
1 (12.5%) 
(2.0% of all patients)
10 
(20.4% of all patients)
6 months after treatment
Euthyreosis 27 (65.8%) (55.1% of all patients)
6 (75.0%) 
(12.2% of all patients)
33 
(67.4% of all patients)
0.83Hypothyroidism 9 (21.9%) (18.4% of all patients)
1 (12.5%) 
(2.0% of all patients)
10 
(20.4% of all patients)
Hyperthyroidism 5 (12.2%) (10.2% of all patients)
1 (12.5%) 
(2.0% of all patients)
6 
(12.2% of all patients)
12 months after treatment
Euthyreosis 25 (61%) (51.0% of all patients)
5 (62.5%) 
(10.2% of all patients)
30 
(61.2% of all patients)
0.99Hypothyroidism 11 (26.8%) (22.4% of all patients)
2 (25.0%) 
(4.1% of all patients)
13 
(26.5% of all patients)
Hyperthyroidism 5 (12.2%) (10.2% of all patients)
1 (12.5%) 
(2.0% of all patients)
6 
(12.2% of all patients)
Table V. Effects of 131I treatment after 12 months
Parameter Women N (%) Men N (%) Total N (%) p
Effective treatment 36 (87.8%) (73.5% of all  patients)
7 (87.5%) 
(14.3% of all  patients)
43 
(87.8% of all patients) 0.57
Hypothyroidism 11 (26.8%) (22.4% of all  patients)
2 (25.0%) 
(4.1% of all  patients)
13 
(22.5% of all patients) 0.74
Euthyreosis 25 (61%) (51.0% of all  patients)
5 (62.5%) 
(10.2% of all  patients)
30 
(61.2% of all patients) 0.75
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in order to prevent cardiovascular risk and to improve 
their quality of life. Our study group showed that the 
clinical symptoms were not limited to the cardiovascu-
lar system. Coexistence of four symptoms in one patient 
was found in as many as 17 subjects (34.7%), which 
means that every third patient had at least four symp-
toms typical for overt hyperthyroidism. In the study 
group 31.7% of women and 50% of men complained 
about emotional lability. The study carried out on the 
basis of the Beck Anxiety Inventory showed that SCH 
patients had significantly higher scores of anxiety than 
their healthy controls [16]. 
In Poland 131I therapy is the treatment of choice 
in patients suffering from hyperthyroidism in the 
course of AFTNs, especially over the age of 60 years, 
who also suffer from cardiovascular diseases [17]. In 
our study, in the majority of the patients (87.7%), RIT 
treatment was effective. After the complete follow-up 
of 12 months from 131I therapy good therapeutic re-
sults were observed in 43 patients (87.8%); 30 patients 
(61.2%) reverted to euthyroidism and 13 patients 
(22.5%) developed hypothyroidism. Our results 
were more encouraging than those of the Australian 
study (79.5% efficacy) [18]. In the study conducted 
by Goldstein et al. 35% of SCH patients treated with 
131I observed from 4 to 16.5 years developed hypothy-
roidism, and its prevalence was not dependent on the 
size of the nodules, thyroid function, or 131I dose [19]. 
However, Mariotti et al. reported hypothyroidism only 
in 4% of the patients and found no correlation between 
the development of hypothyroidism and the size of 
the nodules or the therapeutic dose of 131I [20]. Bolu-
Figure 4. Relationship between initial FT3 level and effects of 
131I treatment
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Figure 5. Relationship between the volume of the thyroid gland 
and effects of 131I treatment
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Figure 3. Relationship between initial FT4 level and effects of 
131I treatment
Figure 2. Effects of 131I treatment after 12 months
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sani et al. included 105 patients with AFTNs in their 
study and observed a rising rate of hypothyroidism 
over time, i.e. in 11% after one year, in 33% after five 
years, and in 49% after 10 years following treatment. 
The development of hypothyroidism did not correlate 
with age, gender, radioiodine uptake, and activity in 
therapy [21]. 
Our study showed correlation between the number 
of coexistent symptoms before the treatment and the 
result of SCH therapy in the course of AFTNs. The pa-
tients who reported the largest number of symptoms 
reverted to euthyreosis or still suffered from SCH. How-
ever, the patients who reported the smallest number of 
symptoms developed hypothyroidism. In the analysis 
of these symptoms and their impact on the effect of 
treatment significant correlation was found only in 
terms of emotional lability. We demonstrated that high 
initial free thyroid hormone levels predisposed patients 
to poorer therapeutic effects. In most of the patients the 
nodule was found in the right lobe (59.2%), whereas in 
20 (40.8%) patients it was found in the left one; in 48.8% 
of women the nodule was located in the left lobe. Inter-
estingly, all AFTNs in men were located in the right lobe, 
for which the literature found no explanation either in 
terms of anatomy or genetics.
Our results showed no link between the volume of 
the nodule and treatment efficacy probably due to the 
small volume of the nodule in our study group.
Although 131I therapy was performed when ex-
tranodular thyroid tissue was suppressed, the larger 
thyroid volume translated into poorer treatment effect. 
This is a surprising observation of the studied popula-
tion, which requires confirmation in further studies 
with larger groups of patients. Nonetheless, Rong et 
al., who examined the above relationship, found no 
such correlation [22]. Also, Massaroi et al. reported no 
link between the size of the thyroid and the effect of 
131I therapy [23].
In our study group the targeted therapeutic effect 
one and three months after treatment was significantly 
more frequent in patients with focal lesions located in 
the right lobe. Such a finding may allow selection of 
a group of patients who reach therapeutic effects much 
faster, and at the same time it may serve as a reason to 
consider various follow-up periods in patients with 
nodules in the left and right lobe. It seems that such 
observations should be confirmed in further studies 
with a larger number of patients because the available 
literature reports no associations between the quality 
and quantity of clinical symptoms and the effect of 131I 
therapy.  
The coexistence of symptoms typical for overt 
hyperthyroidism, which was observed in every third 
patient with SCH, may serve as a basis for modifying 
the definition of this endocrinopathy and consequently 
changing the qualifications for treatment. Distinct clini-
cal pictures of SCH point to the necessity for thorough 
and early diagnostics and treatment, especially in pa-
tients with high cardiovascular risk. Because the treat-
ment of this form of disease is currently controversial 
and the recommendations of international endocrine 
associations are heterogeneous and often questioned 
by renowned endocrinologists, our conclusions could 
serve as valid input in the current debate. 
Conclusions 
1. Most patients with SCH in the course of AFTNs 
suffer from typical symptoms of overt hyperthyroid-
ism; only every sixth patient was asymptomatic.
2. The volume of autonomous adenomas does not af-
fect the result of 131I therapy; however, the impact of 
the thyroid volume on RIT efficacy requires further 
investigation. 
3. In the vast majority of the patients 131I therapy is 
an effective method of treatment and an earlier 
therapeutic effect is observed more often in patients 
with focal lesions located in the right lobe.
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